Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to $364037.0.

  • Iovance Biotherapeutics' Shares Outstanding (Weighted Average) rose 2003.77% to $364037.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $364037.0, marking a year-over-year increase of 2003.77%. This contributed to the annual value of $289877.0 for FY2024, which is 2328.32% up from last year.
  • Iovance Biotherapeutics' Shares Outstanding (Weighted Average) amounted to $364037.0 in Q3 2025, which was up 2003.77% from $334511.0 recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Shares Outstanding (Weighted Average) ranged from a high of $213.7 million in Q1 2023 and a low of $224481.0 during Q2 2023
  • Its 3-year average for Shares Outstanding (Weighted Average) is $19.7 million, with a median of $289877.0 in 2024.
  • The largest annual percentage gain for Iovance Biotherapeutics' Shares Outstanding (Weighted Average) in the last 5 years was 2687.8% (2024), contrasted with its biggest fall of 9987.54% (2024).
  • Iovance Biotherapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $235131.0 in 2023, then rose by 23.28% to $289877.0 in 2024, then rose by 25.58% to $364037.0 in 2025.
  • Its Shares Outstanding (Weighted Average) was $364037.0 in Q3 2025, compared to $334511.0 in Q2 2025 and $322868.0 in Q1 2025.